Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13958743 | 0.95 | TAAR1 (0.50) | TAAR1MAOAHTR7MAOBBACE1 | |
| SCHEMBL13958745 | 0.83 | TAAR1 (0.61) | TAAR1MAOAHTR7FFAR1CYP2A6 | |
| SCHEMBL26313621 | 0.82 | CYP1A2 (0.61) | TAAR1MAOAMAOBBACE1CYP1A2 | |
| SCHEMBL25496067 | 0.82 | CYP4F2 (0.47) | FFAR1IGF1RALOX15 | |
| SCHEMBL20365432 | 0.81 | FFAR1 (0.43) | MAOBFFAR1IGF1RALOX15MPO | |
| SCHEMBL8605570 | 0.80 | TAAR1 (0.74) | TAAR1MAOAHRH1 | |
| SCHEMBL3727224 | 0.80 | TAAR1 (0.54) | TAAR1FFAR1CYP2A6MPO | |
| SCHEMBL4035870 | 0.80 | MAOA (0.57) | TAAR1MAOAHTR7MAOBCYP1A2 | |
| SCHEMBL29706557 | 0.80 | MAOA (0.57) | TAAR1MAOAHTR7MAOBCYP1A2 | |
| SCHEMBL15138999 | 0.80 | MAOA (0.50) | TAAR1MAOAHTR7MAOBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257357-A1 | PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257357-A1 | PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE | NLRP3, PYCARD, NLRP1 | TAAR1 3573/4885MAOA 4327/4885HTR7 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.